在阿尔茨海默氏病中对大麻的分子点进行系统研究
Nil Patil1,2, Khushalika Patil2, Mukul Jain1,2,3
1Cell & Developmental Biology Lab, Research & Development Cell, Parul University, Vadodara, Gujarat, India.
Journal of Alzheimer's disease reports
|March 4, 2025
概括
大麻二醇 (CBD) 通过减少粉样β的产生和提供神经保护来对抗阿尔茨海默病 (AD) 是有前途的. 进一步的研究至关重要,以探索CBD对AD症状和病理学的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种慢性神经退行性疾病,其特征是粉样β (Aβ) 蛋白积累.
- 目前,阿尔茨海默病没有治愈方法,这凸显了对新型治疗策略的需求.
- Cannabidiol (CBD) 是一种非精神活性大麻化合物,目前正在研究其在AD治疗中的潜在治疗作用.
研究的目的:
- 本系统性审查旨在探索各种形式的大麻 (CBD) 对阿尔茨海默病 (AD) 的影响.
- 该审查旨在阐明CBD可以通过神经保护机制在AD中发挥作用的神经保护机制.
主要方法:
- 使用PubMed,Scopus和Web of Science数据库进行了系统的文献搜索.
- 关键词包括"阿尔茨海默病"和"大麻二醇".
- 研究根据标题,摘要和相关性进行了选,具体排除了假设论文,评论和不可用文章.
主要成果:
- 在最初识别的551篇文章中,有22篇被彻底评估.
- 活体和体研究的证据表明,CBD可以破坏Aβ42聚合.
- CBD通过减少炎症,氧化应激,脂质氧化和细胞内过载来显示神经保护作用.
结论:
- 大麻二醇 (CBD) 和其类似物显示出降低粉样β 42 (Aβ42) 生产的潜力.
- 这些发现表明,CBD可能有助于缓解AD病理和症状.
- 需要进一步进行严格的科学研究,才能充分了解CBD在阿尔茨海默病中的治疗应用和机制.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.1K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.6K
相关概念视频
01:26Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
01:22Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145